Patient-perceived risks of MS DMTs: Problems of communication and risk management?

Neurology. 2019 Apr 2;92(14):647-648. doi: 10.1212/WNL.0000000000007230. Epub 2019 Mar 13.

Authors

Gavin V McDonnell¹, James J Marriott²

Affiliations

¹ From the MS Clinic (G.V.M.), Belfast City Hospital, Northern Ireland, UK; and Max Rady College of Medicine (J.J.M.), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada. gavin.mcdonnell@belfasttrust.hscni.net.
² From the MS Clinic (G.V.M.), Belfast City Hospital, Northern Ireland, UK; and Max Rady College of Medicine (J.J.M.), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.

PMID: 30867263
DOI: 10.1212/WNL.0000000000007230

No abstract available

Publication types

Editorial
Comment

MeSH terms

Communication
Drug Tolerance
Humans
Multiple Sclerosis*
Risk Management
Surveys and Questionnaires